ProfileGDS5678 / 1438616_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 40% 39% 39% 37% 38% 41% 41% 39% 39% 40% 39% 38% 39% 39% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9591740
GSM967853U87-EV human glioblastoma xenograft - Control 22.8887439
GSM967854U87-EV human glioblastoma xenograft - Control 32.8951739
GSM967855U87-EV human glioblastoma xenograft - Control 42.8008337
GSM967856U87-EV human glioblastoma xenograft - Control 52.8257638
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0407841
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0085741
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.881639
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8835139
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8926640
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8850239
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8454138
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8920739
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8883339